Andere Sprachen Tevogen Bio Holdings Inc.

Aktien

A402TW

US88165K1016

TVGN

Markt geschlossen - Nasdaq Andere Börsenplätze 22:00:00 14.06.2024			% 5 Tage	% 1. Jan.
0,827 ^USD	-5,82 %		-0,12 %	-92,57 %

06.06.	Tevogen Bio bestätigt anhaltende Wirksamkeit von TVGN 489, seiner allogenen Standard-Immuntherapie, gegen dominante Flirt-Stämme von Sars-Cov-2	CI
13.05.	Anleger erwarten wichtige Inflationsdaten in den kommenden Tagen, US-Futures tendieren am Montag leicht höher	MT

Andere Sprachen

Schalten Sie alle Nachrichten frei: Seien Sie als Erster informiert und reagieren Sie vor den Märkten!

100% kostenlose Registrierung

Tevogen Bio Set to Join Russell 3000® Index	12.06.
Tevogen Bio Enters Into Agreement for Up to $50 Million in Financing to Advance R&D and Clinical Development Efforts	11.06.
CORRECTION – Tevogen Bio Expresses Gratitude to Patients, First Responders, Elected Officials, and Members of the United States Congress for Attending Its Inaugural Post-Public Listing Social Engagement Event	07.06.
Tevogen Bio Confirms Ongoing Efficacy of TVGN 489, Its Investigational Allogeneic Off-the-Shelf Immunotherapy, Against Dominant FLiRT Strains of SARS-CoV-2	06.06.
Tevogen Bio Confirms Ongoing Efficacy of Tvgn 489, Its Investigational Allogeneic Off-The-Shelf Immunotherapy, Against Dominant Flirt Strains of Sars-Cov-2	06.06.
Tevogen Bio Reports First Quarter 2024 Financial Results	29.05.
Tevogen Bio Reports First Quarter 2024 Financial Results	29.05.
Tevogen Bio Appoints Former Police Chief & FBI National Academy Graduate, William Keane, as Vice President of Strategic Initiatives	16.05.
Investors Eye Key Inflation Data in Days Ahead as US Futures Trend Modestly Higher Monday	13.05.
Top Premarket Gainers	13.05.
Tevogen Bio Announces Up to $50 Million in Financing to Further Advance Operational Objectives	10.05.
Tevogen Bio Holdings Inc. announced that it expects to receive $50 million in funding	10.05.
Tevogen Bio Announces Full Year 2023 Financial Results and Upcoming Operational Objectives	01.05.
Sector Update: Health Care Stocks Higher in Afternoon Trading	26.04.
Tevogen Bio Shares Jump Following Report on $94.9 Million Liability Elimination	26.04.
Tevogen Bio CEO Highlights Expected Reporting of a $94.9 Million Liability Elimination, AI Initiative, and Leadership Appointments	26.04.
Top Premarket Gainers	26.04.
Tevogen Bio’s Chief Scientific Officer Speaks on the Harnessing of Cytotoxic T Lymphocytes (CTLs) to Target Cancers	11.04.
Top Premarket Gainers	04.04.
Tevogen Bio Appoints Tapan V Shah as Head of Investor Relations and Corporate Development	03.04.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Tevogen Bio Holdings Inc.

Aktien

A402TW

US88165K1016

TVGN

Andere Sprachen

Filter